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Abstract
The cost-effectiveness and benefit of many diagnostic tests used in the presurgical evaluation for persons with epilepsy is
for the most part uncertain as is their influence on decision-making. The options we have at our disposal are ever
increasing. Advanced imaging modalities aim to improve surgical candidacy by helping us better define the epileptogenic
zone and optimize surgical planning. However, judicious use is important. Randomized controlled trials delineating which
mode of investigation is superior are lacking. Presurgical tests do have incremental value by increasing surgical candidacy
and refining surgical planning. The yield of additional imaging will increase with complex localization. However, every case
must be tailored by hypothesis, cost, and accessibility. Future studies using a quantitative cost–benefit framework are
needed to determine the cost-effectiveness of advanced diagnostic tests (beyond magnetic resonance imaging) in the
presurgical evaluation of those with epilepsy.
Keywords
epilepsy surgery, cost-effectiveness, imaging, MRI, PET, SPECT, MEG, presurgical work up
Introduction
This review is a recount of the debate at the Annual Course at
the American Epilepsy Society 2018 Meeting in New Orleans,
Louisiana. This symposium aimed to examine the cost-
effectiveness of advanced diagnostic technologies as well as
discuss the knowledge gaps and future directions in the pre-
surgical evaluation of those with epilepsy. The focus of this
narrative review is on the cost-effectiveness of these tools in
those undergoing a presurgical evaluation rather than their
accuracy or concordance with other clinical data. The chal-
lenges related to determining the cost-effectiveness of various
diagnostic technologies for epilepsy surgery are also
discussed.
Discussion
The etiology of epilepsy is multifaceted and, in many patients,
remains unclear. Identifying the cause of epilepsy is a funda-
mental component in the clinical management of such patients.
In recent years, new diagnostic modalities have revolutionized
our capacity to investigate and identify the underlying causes
of epilepsy. Classically, imaging along with electroencephalo-
graphy (EEG) has been the fundamental tool in the workup of
those with epilepsy, as successful treatment of epilepsy, par-
ticularly drug-resistant epilepsy, is governed by how accurately
the epileptogenic zone is identified.1 All patients with epilepsy
should undergo magnetic resonance imaging (MRI) as a first
step to assist in establishing the cause of their epilepsy and to
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attempt to determine whether there is a lesion associated with
their epilepsy, since the identification of an associated lesion is
associated with greater odds of seizure freedom after surgery.2
Resective surgery is the gold standard for the treatment of
focal drug-resistant epilepsy in appropriately selected
patients.3-5 Seizure freedom can be achieved for significant
proportion of patients; the number needed to treat with surgery
for 1 additional patient to become seizure-free is 2. A rando-
mized controlled trial (RCT) comparing medical treatment to
early surgery in those with temporal lobe epilepsy (TLE) found
64% of patients in the surgical arm were seizure-free in the first
year of follow-up versus 8% in the medically treated arm.3
Long-term outcomes are also good with 10-year follow-up
studies showing that 50% to 60% of those who undergo TLE
resection, and 30% to 40% of those who undergo frontal lobe
resection remain seizure-free.6-8 Thus, it is critical to identify
ideal surgical candidates. The success of surgical resection is
dependent on localization of the epileptogenic zone and com-
plete resection of known epileptogenic cortex. Surgical failure
is more common in cases of contralateral hippocampal sclero-
sis, remnant ipsilateral hippocampus, or temporal-plus epilepsy
(extension to insula, orbitofrontal region, operculum, and tem-
poroparietal junction, even extension into extratemporal com-
ponents of the limbic network and thalamus).9-11 Advanced
imaging is performed in order to help determine surgical can-
didacy and improve the presurgical identification of the epilep-
togenic zone. Such processes ultimately aid in surgical
planning to guide the placement of intracranial electroencepha-
lography (iEEG) electrodes, the extent of resection needed,
placement of responsive neurostimulation device, or determine
whether other surgical approaches may also be considered (eg,
later interstitial thermal therapy [LITT] and deep brain stimu-
lation [DBS]). The benefit of advanced diagnostic technology
depends not only on its diagnostic accuracy but also on how the
results impact subsequent treatment decisions as well as the
final clinical outcomes (eg, seizure control and safety) and
economic benefits.12 The RCTs delineating which mode of
investigation is superior are lacking. A recent meta-analysis
using epilepsy surgical data from the 3 RCTs on TLE in adults
as well as class II data from prospective studies found remark-
able concordance at approximately 70% seizure freedom across
studies.13 As future RCTs with TLE will continue to have
recruitment challenges, this may act as a reasonable historical
control for future surgical therapies (eg, LITT).
The options we have at our disposal are ever increasing.
Nuclear medicine techniques that determine metabolic, in vivo
perfusion, and neurotransmission changes associated with a
seizure, although not used in the primary diagnosis of new-
onset epilepsy, have afforded essential functional data in the
presurgical evaluation of drug-resistant epilepsy. Nuclear med-
icine imaging modalities are particularly beneficial if the MRI
is nonlesional or exhibits multiple lesions or if EEG changes
are discordant with structural imaging. Positron emission
tomography (PET) and single photon emission computed
tomography (SPECT) are also helpful when interrogating the
remaining functional integrity of the brain in these patients.
Other noninvasive imaging techniques such as simultaneous
recording of functional magnetic resonance imaging and EEG
(EEG-fMRI), magnetic source imaging (MSI), and magnetoen-
cephalography (MEG) can be useful in defining the epilepto-
genic zone.14,15 These investigations however are expensive
(eg, high equipment costs) and typically labor-intense with
much expertise needed.
The Challenges of Evaluating the Cost of
Epilepsy Diagnostic Technologies
There are challenges in evaluating the cost of epilepsy technol-
ogies. It is important to keep in mind that >85% of the world’s
50 million people with epilepsy live in low-resource countries,
where many diagnostic and therapeutic options are not avail-
able. There are limited facilities and personnel, implementation
of new technologies in these regions may not be financially or
practically feasible, and competition for resources and alloca-
tion is often based on political decisions. A Health Technology
Assessment report on neuroimaging modalities used to identify
a seizure focus in drug-resistant epilepsy was first published in
2006 and updated in 2010. These reports identified that there
remained a lack of accuracy and cost-effectiveness studies
linking test results, management, and clinical outcomes in the
presurgical evaluation of those with epilepsy.16,17 Limitations
of existing studies include the fact that most studies only
include operated patients, the follow-up is often short with
small sample sizes, and there is a lack of detailed cost analysis
(eg, direct, indirect, and intangible costs).
Do we know the true cost-effectiveness of diagnostic tech-
nologies for epilepsy surgery? Not really. An ideal pathway in
the presurgical workup for epilepsy that weighs the benefits,
risks, and costs associated with advanced diagnostic technolo-
gies is necessary. Limited research has been conducted inves-
tigating the clinical effectiveness and cost-effectiveness of
advanced imaging studies used to visualize the seizure focus
in people being considered for epilepsy surgery.18 This may be
partly due to the challenges of assessing the cost of an addi-
tional mode of imaging with minimal consensus on analytical
techniques. It is also difficult to attribute the benefit of an
additional diagnostic test to long-term outcomes. As there are
levels of evidence for therapeutic studies, a hierarchy in diag-
nostic research has been proposed.19-21 At the lower end of the
hierarchy, studies tend to evaluate diagnostic performance,
while at the higher end clinical- and cost-effectiveness are
appraised.22 The following elements have been proposed when
evaluating the cost-effectiveness of diagnostic tests (Table 1):
(1) the test characteristics, that is, the parameters that determine
the accuracy, sensitivity, specificity, and predictive values of
the tests; (2) a robust knowledge about the clinical value of the
test, that is, additional information from the test in sequence,
rather than in isolation is required; (3) the clinical outcome is
vital to the overall evaluation that is, the justification to do it
is not for direct test results but potential access to surgery; and
(4) the cost-effectiveness analysis is the only appropriate way
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to be able to combine all the information collected in the first
3 steps.21
Positron Emission Tomography
The abovementioned framework was applied to PET in a sys-
tematic review on clinical and economic benefits of diagnostic
testing for TLE surgery, when video-EEG (vEEG) and MRI are
non-localizing or discordant. Fluorodeoxyglucose (FDG)-PET
þ iEEG after discordant or nonlocalizing vEEG and MRI
“appear” cost-effective but only if the benefits are sustained
in the long term.12 Added value is inextricably linked to the
decision to proceed to surgery and cost-effectiveness, particu-
larly when used in patients with nonlocalizing or nonconcor-
dant vEEG/MRI.23,24 Limitations to this study include the
limited assessment to vEEG and MRI alone, use of FDG-
PET alone, and use of FDG-PET and iEEG. Although showing
promise, this study is still an oversimplification of the wide
range of diagnostic modalities available to clinicians.12
Another FDG-PET study examined whether FDG-PET sub-
stantially altered decision-making in drug-resistant epilepsy
and found that there was greater concordance with TLE than
with extra-TLE (78.0% vs 28.6%, P < .001). One-third of the
patients were selected for resective surgery based on PET, and
associated costs escalated by 13.0% when PET was used
(unless iEEG was avoided). Positron emission tomography
when applied judiciously remained a supplementary tool in the
surgical selection of one-third of patients with drug-resistant
partial epilepsy; however, its application as a separate tool was
not as promising.25
Single Photon Emission Computed Tomography
Cost-effectiveness data about additional diagnostic modalities
(eg, SPECT or MEG) in the presurgical evaluation of epilepsy
are scarce. This explains partially why these tests are not
ordered at once but rather serially, since the added value
diminishes with each test, especially if one already gives rea-
sonable localizing information. A recent study from the United
Kingdom looked at the relationship between MRI, EEG, and
SPECT and the probability of a child being offered epilepsy
surgery.26 The study included 353 children discussed at pre-
surgical multidisciplinary rounds of which 236 were offered
surgery. It showed that MRI and EEG were independently
useful in identifying children with localized seizure onset. The
proportion of children offered surgery with a single lesion on
MRI was 92% (95% confidence interval [CI]: 88%-95%), and
EEG did not modify decision-making in such cases (P < .001).
In children who had bilateral MRI changes or normal scans,
surgery was offered in 78% of those with localized EEG onset
versus 9% with nonlocalized onset (P < .001). Magnetic reso-
nance imaging provided the most powerful data for surgical
planning, while SPECT did not appear to systematically influ-
ence decision-making in any group.26 In a Spanish study that
looked at 34 consecutive patients with interictal brain SPECT
abnormalities when the seizure focus was identified with vEEG
or MRI brain, SPECT did not offer any additional information
regarding surgical decision-making.27 Although unlikely to
provide additional information in some patients, SPECT can
be useful in selected groups of patients, especially in those with
lesional TLE with nonlocalizing ictal data and in those with
dual pathologies.28 Single photon emission computed tomogra-
phy is costly with radiotracers having short half-lives and the
fact that multiple fillings are usually needed for a successful
SPECT completion. One also requires the presence of an EEG
technologist and/or a trained nurse to ensure timely injection of
radiotracer.
Magnetoencephalography
When standard noninvasive diagnostic tests cannot sufficiently
localize the potential epileptogenic zone, additional ancillary
tests are necessary. A cost-utility study analyzed MEG use to
inform intracranial electrode placement in those with drug-
resistant epilepsy and found that it was not cost saving.29
However, this study had several limitations. Although peer-
reviewed literature was used to inform the model, most studies
were of small sample size, and no RCTs existed. Many factors
can influence surgical outcomes including the diagnostic tech-
nologies available for surgical planning, the skill and experi-
ence of the diagnostic and surgical teams, and the etiology of
the epilepsy. The authors went on to acknowledge that the
study likely overstated the effectiveness of MEG by attributing
diagnostic yield of FDG-PET and SPECT to MEG.29
Functional Magnetic Resonance Imaging
Other modalities are increasingly being utilized in the presur-
gical evaluation of epilepsy. The American Academy of Neu-
rology published a practice guideline in 2017 on the use of
fMRI for the presurgical evaluation of epilepsy.30 A systematic
review looking at the diagnostic accuracy of fMRI, amobarbital
testing, MEG, functional transcranial Doppler (fTCD)
Table 1. Hierarchy in Diagnostic Research.a
Step 1: Test
characteristics
Evaluate the parameters that determine the
positive-predictive value, negative-predictive
value, sensitivity, and specificity of the tests.
Assess the likelihood ratios characterizing the
change in probability of disease after the test
vs before the test.
Step 2: Added value
of a test
Robust knowledge about the clinical value of the
test, that is, additional information from the
test in sequence rather than isolation is
required
Step 3: Clinical
outcome
The justification to do diagnostic test is not for
direct test results but potential access to
epilepsy surgery
Step 4: Cost-
effectiveness
Cost-effectiveness analysis is the only
appropriate way to be able to combine all the
information collected in the first 3 steps
aAdapted from Schaafsma et al.21
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sonography to predict memory and language outcomes after
surgery found that the overall quality of the evidence was very
low.15 Meta-analyses of the diagnostic accuracy of fMRI,
MEG, and fTCD were not feasible due to small number of
studies. Only the diagnostic accuracy of amobarbital to predict
memory outcome could be evaluated, yielding a sensitivity of
0.79 (95% CI: 0.67-0.92) and specificity of 0.65 (95% CI: 0.47-
0.83). It was also noted that high variability existed between
protocols, stimuli, neuropsychological testing, and assessments
of language and memory function.15
Conclusions
The cost-effectiveness of many diagnostic tests used in the
presurgical evaluation for persons with epilepsy is for the most
part uncertain as is their influence on decision-making. How-
ever, lack of high-quality evidence does not equate to lack of
cost-effectiveness. There is a need to examine the cost-
effectiveness of diagnostic tests in everyone who has a test,
not just those who undergo surgery, as there would be an
inherent selection bias. Studies examining which advanced
imaging and EEG modalities effectively contribute do
decision-making and improve surgical outcomes in epilepsy
are also warranted. More high-quality studies addressing the
cost-effectiveness of newer presurgical investigations are
needed.
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